AR109898A1 - Perlas multicapa para uso farmacéutico - Google Patents

Perlas multicapa para uso farmacéutico

Info

Publication number
AR109898A1
AR109898A1 ARP170102802A ARP170102802A AR109898A1 AR 109898 A1 AR109898 A1 AR 109898A1 AR P170102802 A ARP170102802 A AR P170102802A AR P170102802 A ARP170102802 A AR P170102802A AR 109898 A1 AR109898 A1 AR 109898A1
Authority
AR
Argentina
Prior art keywords
drug
polymer
layer
hept
difluoro
Prior art date
Application number
ARP170102802A
Other languages
English (en)
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR109898A1 publication Critical patent/AR109898A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulgan perlas multicapa para uso farmacéutico que tienen una capa de fármaco en polímero. Las perlas multicapa divulgadas para uso farmacéutico tienen (a) una partícula de núcleo; (b) una capa de barrera opcional que recubre la superficie de la partícula de núcleo; (c) una capa de fármaco en polímero que recubre la superficie del núcleo o la capa de barrera, (d) una capa selladora opcional que recubre la superficie de la capa de fármaco en polímero; y (e) opcionalmente una o más capas exteriores externas a la capa de fármaco en polímero o la capa selladora. La capa de fármaco en polímero consiste esencialmente en (i) un fármaco seleccionado del grupo que consiste en un fármaco de 15-ceto prostaglandina, un fármaco de 13,14-dihidro prostaglandina, y un fármaco de 13,14-dihidro-15-ceto prostaglandina; y (ii) un polímero seleccionado del grupo que consiste en polivinilpirrolidona, copolímero de vinilpirrolidona-vinilacetato o una de sus mezclas. La capa de fármaco en polímero puede ser una dispersión sólida del fármaco en el polímero. Se divulgan además composiciones farmacéuticas que comprenden una pluralidad de perlas multicapa y un excipiente farmacéuticamente aceptable y métodos de tratamiento de un trastorno gastrointestinal. Reivindicación 2: Una perla multicapa de la reivindicación 1, donde el fármaco es seleccionado del grupo que consiste en: ácido (-)-7-[(2R,4aR,5R,7aR)-2-(1,1-difluorpentil)-2-hidroxi-6-oxooctahidrociclopenta[b]piran-5-il]heptanoico (lubiprostona); ácido (-)-7-{(2R,4aR,5R,7aR)-2-[(3S)-1,1-difluoro-3-metilpentil]-2-hidroxi-6-oxooctahidrociclopenta[b]piran-5-il}heptanoico (cobiprostona); (+)-isopropil (Z)-7-[(1R,2R,3R,5S)-3,5-dihidroxi-2-(3-oxodecil)ciclopentil]hept-5-enoato, (isopropil unoprostona); ácido (Z)-7-[(1R,2R,3R,5S)-3,5-dihidroxi-2-(3-oxodecil)ciclopentil]hept-5-enoico; ácido (-)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctil)-5-oxociclopentil]heptanoico; y ácido (E)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctil)-5-oxociclopentil]hept-2-enoico.
ARP170102802A 2016-10-06 2017-10-06 Perlas multicapa para uso farmacéutico AR109898A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662405131P 2016-10-06 2016-10-06

Publications (1)

Publication Number Publication Date
AR109898A1 true AR109898A1 (es) 2019-02-06

Family

ID=60543581

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102802A AR109898A1 (es) 2016-10-06 2017-10-06 Perlas multicapa para uso farmacéutico

Country Status (5)

Country Link
US (1) US11534404B2 (es)
JP (1) JP6957610B2 (es)
AR (1) AR109898A1 (es)
TW (1) TW201815383A (es)
WO (1) WO2018065826A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6957610B2 (ja) 2016-10-06 2021-11-02 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 医薬品用途のための多層ビーズ
EP3551173A1 (en) * 2016-12-09 2019-10-16 Bayer Animal Health GmbH Pharmaceutical preparation and method for its manufacture
WO2019221215A1 (ja) * 2018-05-18 2019-11-21 ニプロ株式会社 ルビプロストン含有粒子状医薬組成物
CN109701461B (zh) * 2018-10-25 2021-06-08 西南交通大学 一种基于PEG/Dex双水相的碳酸钙/海藻酸钙复合微囊的制备及其应用
JP2020075874A (ja) * 2018-11-06 2020-05-21 ニプロ株式会社 ルビプロストン含有フィルム状医薬組成物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5942313A (ja) * 1982-09-01 1984-03-08 Teijin Ltd ポリビニルポリピロリドンを用いた製剤
JPS6377821A (ja) * 1986-09-19 1988-04-08 Teikoku Seiyaku Kk 安定なプロスタグランジンｅ組成物
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
DE69213057T2 (de) * 1991-03-14 1997-01-09 Ueno Seiyaku Oyo Kenkyujo Kk Stimulierung von Wundheilung mit 15-Keto-prostaglandinverbindungen
ATE402925T2 (de) 1999-10-15 2008-08-15 Sucampo Ag Neue zusammensetzung enthaltend eine bicyclische verbindung und ein glycerid
DE19962544A1 (de) 1999-12-23 2001-07-19 Degussa Verfahren zum Beschichten eines keramischen Wabenkörpers
KR100874626B1 (ko) * 2000-04-06 2008-12-17 수캄포 아게 담즙 분비 촉진 조성물
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
KR100867295B1 (ko) 2001-05-18 2008-11-06 수캄포 아게 하제 조성물
CA2458471C (en) 2001-08-31 2012-07-31 Sucampo Ag Prostaglandin analogs as chloride channel opener
JP2005139085A (ja) * 2003-11-04 2005-06-02 Ono Pharmaceut Co Ltd 顆粒
CN101111230B (zh) * 2005-03-29 2010-05-19 赢创罗姆有限责任公司 包含对活性成分具有调节释放作用的小丸的多颗粒药用形式
BRPI0707334B8 (pt) 2006-01-24 2021-05-25 R Tech Ueno Ltd formulação de cápsula de gelatina mole de um composto 15-ceto-prostaglandina e método para estabilização do um composto 15-cetoprostaglandina
BRPI0716481A2 (pt) * 2006-09-04 2014-03-18 Panacea Biotec Ltd Tecnologia de liberação flutuante programável
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
US20100136110A1 (en) * 2008-09-30 2010-06-03 Astellas Pharma Inc. Granular pharmaceutical composition for oral administration
CA2758258A1 (en) * 2009-04-09 2010-10-14 Alkermes Pharma Ireland Limited Drug delivery composition
CA2771539A1 (en) * 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
US20160120840A1 (en) 2014-10-30 2016-05-05 Sucampo Ag Method and composition for treating nonerosive reflux disease
EP3463307A4 (en) * 2016-06-03 2020-01-15 Velicept Therapeutics, Inc. COMPOSITIONS AND METHODS FOR USE OF SOLABEGRON WITH MODIFIED RELEASE FOR SYMPTOMS OF THE LOWER URINARY PATHWAYS
JP6957610B2 (ja) 2016-10-06 2021-11-02 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 医薬品用途のための多層ビーズ

Also Published As

Publication number Publication date
WO2018065826A1 (en) 2018-04-12
JP6957610B2 (ja) 2021-11-02
US20200390708A1 (en) 2020-12-17
JP2019529467A (ja) 2019-10-17
TW201815383A (zh) 2018-05-01
US11534404B2 (en) 2022-12-27

Similar Documents

Publication Publication Date Title
AR109898A1 (es) Perlas multicapa para uso farmacéutico
Niu et al. Protective effect of sanguinarine against acetic acid-induced ulcerative colitis in mice
Tobin Host-directed therapies for tuberculosis
JP2022066315A (ja) 注意欠陥障害の処置のための方法および組成物
JP2014528431A5 (es)
WO2011123836A3 (en) Pharmaceutical formulations for the treatment of overactive bladder
RU2014110184A (ru) Комбинации терапевтических средств, предназначенные для лечения рака
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
RU2014124184A (ru) Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5
EA200900270A1 (ru) Системы регулируемого высвобождения и способ их приготовления
AR075148A1 (es) Formulacion de rasagilina de liberacion retardada. proceso para fabricar citrato de rasagilina
JP2014503523A5 (es)
JP2019529467A5 (es)
RU2013122656A (ru) Композиции и способы доставки терапевтических средств
WO2014027334A3 (es) Composicion farmacéutica oral en forma de microesferas y proceso de elaboración
RU2014127884A (ru) Способы лечения сердечно-сосудистого нарушения
JP2017528497A5 (es)
HRP20210010T1 (hr) Injekcijske farmaceutske formulacije lefamulina
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
JP2008532967A5 (es)
AR038141A1 (es) Composiciones farmaceuticas estables que comprenden inhibidor(es) de ace
CA2794655A1 (en) Method for treating schizophrenia and related diseases
CN105338975B (zh) 用于治疗癌症的氧烯洛尔组合物
CN113896628A (zh) 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
WO2012156997A3 (en) Multi-particulate pharmaceutical composition

Legal Events

Date Code Title Description
FB Suspension of granting procedure